Thrombopoietin Receptor Agonists: A Critical Review

William B. Mitchell, James B. Bussel

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalSeminars in Hematology
Volume52
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Thrombopoietin Receptors
Safety
Idiopathic Thrombocytopenic Purpura
Health Services Needs and Demand
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombopoietin Receptor Agonists : A Critical Review. / Mitchell, William B.; Bussel, James B.

In: Seminars in Hematology, Vol. 52, No. 1, 01.01.2015, p. 46-52.

Research output: Contribution to journalReview article

Mitchell, William B. ; Bussel, James B. / Thrombopoietin Receptor Agonists : A Critical Review. In: Seminars in Hematology. 2015 ; Vol. 52, No. 1. pp. 46-52.
@article{8bdce939ea3745dcbecaf3e56bd564a2,
title = "Thrombopoietin Receptor Agonists: A Critical Review",
abstract = "Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.",
author = "Mitchell, {William B.} and Bussel, {James B.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1053/j.seminhematol.2014.11.001",
language = "English (US)",
volume = "52",
pages = "46--52",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Thrombopoietin Receptor Agonists

T2 - A Critical Review

AU - Mitchell, William B.

AU - Bussel, James B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.

AB - Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging. The purpose of this review will be to focus critically on what we know or do not know at this point about these agents. We review the evolution, efficacy and clinical use, side effects, special populations, and off-target effects of the thrombopoietic agents.

UR - http://www.scopus.com/inward/record.url?scp=84920670950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920670950&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2014.11.001

DO - 10.1053/j.seminhematol.2014.11.001

M3 - Review article

C2 - 25578419

AN - SCOPUS:84920670950

VL - 52

SP - 46

EP - 52

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 1

ER -